Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200-500 CD4 cells/mm3 (ACTG 175)

Janet L. Lathey, Michael D. Hughes, Susan A. Fiscus, Timothy Pi, J. Brooks Jackson, Suraiya Rasheed, Tarek Elbeik, Richard Reichman, Anthony Japour, Richard T. D'Aquila, Walter Scott, Brigitte P. Griffith, Scott M. Hammer, David A. Katzenstein

Research output: Contribution to journalArticlepeer-review

43 Scopus citations


Virologic measurements are increasingly used to evaluate prognosis and treatment responses in human immunodeficiency virus (HIV) type 1 infection. Markers of HIV-1 replication, including infectious HIV-1 titer from peripheral blood mononuclear cells, serum HIV-1 p24 antigen, plasma HIV-1 RNA, CD4 cell numbers, and viral syncytium-inducing (SI) phenotype, were determined in 391 virology substudy participants in AIDS Clinical Trials Group study 175. The subjects had 200-500 CD4 cells/mm3. All markers of viral replication significantly correlated with one another and were inversely related to CD4 cell number. Disease progression to an AIDS-defining event or death or loss of >50% of CD4 cells was associated with infectious HIV-1 titer (P < .001), HIV-1 RNA (P < .001), and HIV-1 p24 antigen (P = .007). In multivariate proportional hazards models, p24 antigen was never significant when HIV-1 RNA level was included. In a model containing infectious HIV-1 titer (P = .038), HIV-1 RNA (P < .001), SI phenotype (P < .001), and CD4 cell number (P = .18), only the virologic parameters remained significantly associated with progression.

Original languageEnglish (US)
Pages (from-to)617-624
Number of pages8
JournalJournal of Infectious Diseases
Issue number3
StatePublished - 1998

Bibliographical note

Funding Information:
Received 20 May 1997; revised 29 September 1997. Presented in part: 4th Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 1997 (abstract 543). Informed consent was obtained from all study participants. The study followed the human experimentation guidelines of the US Department of Health and Human Services. Grant support: NIH: AI-27670, AI-38858, and AI-36214 (to J.L.L.); AI-25868, VC-006, and RR-00046 (to S.A.F.); AI-65304 (to J.B.J.); AI-27658 and RR-0004 (to R.R.); AI-27659 and AI-29193 (to R.D.); and AI-27560 (to W.S.). Reprints or correspondence: Dr. Janet L. Lathey, Dept. of Pediatrics, University of California, San Diego, 9500 Gilman Dr., #0672, La Jolla, CA 92093-0672 ( * Present affiliation: Abbott Laboratories, Abbott Park, Illinois.

Fingerprint Dive into the research topics of 'Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200-500 CD4 cells/mm<sup>3</sup> (ACTG 175)'. Together they form a unique fingerprint.

Cite this